DPTX3186 in Wnt Pathway Activated Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available. * At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI. * ECOG performance status of 0 or 1. * Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy. * Age ≥18 years (or ≥ age of majority per local regulation) * Life expectancy ≥3 months * Willing and able to comply with protocol requirements Exclusion Criteria: * Symptomatic or uncontrolled brain metastasis requiring concurrent treatment, * Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.). * Inadequate organ function * Known hypersensitivity to study drug or excipients